Citigroup Maintains Buy on Applied Therapeutics, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz has maintained a Buy rating on Applied Therapeutics (NASDAQ:APLT) and raised the price target from $7 to $8.
August 27, 2024 | 2:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup's analyst Yigal Nochomovitz has reaffirmed a Buy rating for Applied Therapeutics and increased the price target from $7 to $8, indicating positive sentiment and potential upside.
The reaffirmation of a Buy rating and an increase in the price target by a major financial institution like Citigroup suggests confidence in Applied Therapeutics' future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100